文献速递流行病学与生物统计临床试验与 GCP

多数随机试验荟萃分析适用的危害结局报告:临床流行病学关键概念

Harm outcomes applicable for most meta-analyses of randomized trials of biomedical interventions: a key concept in clinical epidemiology.
PubMed 文献 · J Clin Epidemiol · 2026-03-07

随机试验通过随机化减少混杂与选择偏倚,但危害报告仍不理想。作者建议试验者分享系统或非系统评估的危害信息,并明确测量内容、时间与人员,按组提供所有观察到的危害数据,不应设阈值限制分享。

要点

  • 试验者应报告系统与非系统评估的所有危害,明确测量内容、时间与人员。
  • 按组提供二分类危害数据:风险人数、死亡数、不良事件人数、因危害退出数及总事件数。
  • 不应设阈值限制危害信息分享;系统评估的危害应包含零事件。

核心结论

  • 改善危害报告可提升证据合成质量、增强可解释性,并支持知情临床决策与患者安全。

研究设计与样本

  • 本文为临床流行病学关键概念论述,非系统检索或原始研究。

主要发现

  • 随机试验中危害报告仍不理想,非系统评估的不良事件常被低报或记录不一致。

关键数值与推荐

  • 二分类结局应按组提供风险人数(随机化个体)、死亡数、一个或多个不良事件人数、因危害退出数及总事件数(如适用)。
  • 系统评估的危害应包含零事件;合并不良事件应分享所有组成部分事件的数据。

临床怎么用

  • 试验者应按组以表格或数据形式分享所有观察到的危害,不设阈值限制信息分享。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Randomized trials are used to evaluate health care interventions because they minimize confounding and selection bias through randomization. Harms reporting in trials remain suboptimal, despite established guidelines. To improve transparency and clinical relevance, trialists should share information about harms-whether assessed systematically or nonsystematically. Nonsystematically assessed adverse events warrant greater attention, as they are often underreported or inconsistently documented. Trialists should specify what was measured, when, and by whom. For each study arm, tables or data should be available that include all harms observed. For dichotomous outcomes, tables or data should include the number of people who experienced each harm in each group: the number of participants at risk of harms (ie, randomized individuals); the number of deaths; participants with one or more adverse events; withdrawals (discontinuations) due to harms; and the total number of events, if appropriate. Thresholds should not be used to limit the sharing of information about harms. Zero events should be included for harms systematically assessed. For combined adverse events, such as the proportion of participants with one or more serious adverse events, researchers should report or share data for all component events (eg, deaths, major cardiovascular events, cancers, infections, and psychiatric events). Better harms reporting could improve evidence synthesis, enhance interpretability, and support informed clinical decision-making as well as patient safety.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Christensen R, Berthelsen DB, Tugwell P, et al. Harm outcomes applicable for most meta-analyses of randomized trials of biomedical interventions: a key concept in clinical epidemiology. J Clin Epidemiol. 2026. PMID: 41802580. doi:10.1016/j.jclinepi.2026.112218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。